Alembic Pharmaceuticals gets FDA approval for Formoterol Fumarate Inhalation Solution

TAGS

Alembic Pharmaceuticals said that it has secured final approval from the (FDA) for Formoterol Fumarate Inhalation Solution, 20 mcg/2 ml per Unit-Dose Vial.

The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to Perforomist Inhalation Solution, 20 mcg/2 ml per Unit-Dose Vial, the reference listed drug product (RlD) owned by .

See also  OncoVerity accelerates AML treatment with Series A extension

According to , Formoterol Fumarate Inhalation Solution is a long-acting beta2-adrenergic agonist (beta2-agonist) approved to be used for lonq-term, twice daily for the maintenance treatment of bronchoconstriction in patients suffering from chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis.

The ANDA has been jointly developed with .

According to IQVIA, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ml per Unit-Dose Vial, has an estimated market size of $310 million for 12 months ending September 2021.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This